Pantuck, A.J., Ophoven, A.V., Gitlitz, B.J., Tso, C.L., Acres, B., Squiban, P., Belldegrun, A.S., Figlin, R.A., Phase I Trial of Antigen-Specific Gene Therapy Using a Recombinant Vaccinia Virus Encoding MUC-1 and IL-2 Positive Patients with Advanced Prostate Cancer, J Immunotherapy, 27(3): 240-253, 2004.
Pantuck, A.J., Zeng, G., Belldegrun, A.S., Figlin, R.A., Pathobiology, Prognosis and Targeted Therapy for Renal Cell Carcinoma: Exploiting the Hypoxia-Induced Pathway, Clin Cancer Res, 9(13):4641-52, 2003.
Gitlitz, B.J., Belldegrun, A.S., Zisman, A., Chao, D.H., Pantuck, A.J., Hinkel, A., Mulders, P., Moldawer, N., Tso, C.L., Figlin, R.A., A Pilot Trial of Tumor Lysate-Loaded Dendritic Cells for the Treatment of Metastatic Renal Cell Carcinoma, J Immunotherapy, 26:412-419, 2003.
Hernandez, J.M., Bui, M., Han, K., Mukouyama, H., Freitas, D.G., Nguyen, D., Caliliw, R., Shintaku, P.I., Paik, S.H., Tso, C.L., Figlin, R.A., Belldegrun, A.S., Novel Kidney Cancer Immunotherapy Based On The Granulocyte-Macrophage Colony-Stimulating Factor and Carbonic Anhydrase IX Fusion Gene, Clin Cancer Res, 9;1906-1916, 2003.
Bui, M, Seigson, D, Han, K, Pantuck, A, Dorey, F, Huang, Y, Horvath, S, Leibovich, B, Chopra, S, Liao, S, Stanbridge, E, Lerman, M, Palotie, A, Figlin, RA, Belldegrun, A, Carbonic Anhydrase IX is an Independent Predictor of Survival in Advanced Renal Cell Carcinoma: Implications for Prognosis and Therapy, Clin Cancer Res, 9:802-811, 2003.
Zisman, A, Pantuck, A, Wieder, J, Chao, D, Dorey, F, Said, J, deKernion, J, Figlin, RA, Belldegrun, A, Risk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients with Surgically Resected Renal Cell Carcinoma, J Clin Oncol, 20:4559-4566, 2002.
Zisman, A, Pantuck, AJ, Dorey, F, Said, JW, Shvarts, O, Quintana, D, Gitlitz, J, deKernion, JB, Figlin, RA, Belldegrun, AS, Improved Prognostication of RCC Using An Integrated Staging System (UISS), J Clin Oncol, 19:1649-1657, 2001.
Pantuck, AJ, Belldegrun, AS, Figlin, RA, Nephrectomy and Interleukin-2 for Metastatic Renal Cell Carcinoma, N Engl J Med, 345(23), 1711-1712, 2001.
Roth, MD, Gitlitz, BJ, Kiertscher, SM, Park, AN, Mendenhall, M, Moldawer, N, Figlin, RA, Granulocyte/Macrophage-Colony Stimulating Factor and Interleukin-4 Enhance the Number and Antigen-Presenting Activity of Circulating CD14+ and CD83+ Cells in Cancer Patients, Cancer Res, 60, 1934-1941, 2000.
Figlin, RA, Thompson, JA, Bukowski, RM, Vogelzang, NJ, Novick, AC, Lange, P, Belldegrun, A, A Multicenter Randomized PhaseII/III Trial of CD8+ Tumor Infiltrating Lymphocytes in Combination with Recombinant Interleukin-2 in Metastatic Renal Cell Carcinoma, J Clin Oncol, 17:2521-2529, 1999.
Figlin RA. Renal cell carcinoma: management of advanced disease. J Urol 161(2):381-386, 1999.
Figlin RA, Pierce WC, Kaboo R, Tso CL, Moldawer N, Gitlitz B, deKernion J, Belldegrun A. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol 158:740-745, 1997.
Belldegrun, A., Pierce, W., Kaboo, R., Tso, C.-L., Shau, H., Turcillo, P., Moldawer, N., Golub, S., deKernion, J., Figlin, R.A., Interferon Alpha-Primed Tumor Infiltrating Lymphocytes Combined with Interleukin-2 and Interferon-Alpha as Therapy for Metastatic Renal Cell Carcinoma, J Urol, 150, 1384-1390, 1993.
Figlin, R.A., Belldegrun, A., Moldawer, N., Zeffren, J, and deKernion, J., Concomitant Administration of Recombinant Human Interleukin-2 and Recombinant Interferon Alfa-2A: An Active Regimen in Metastatic Renal Cell Carcinoma, J Clin Oncol, 10:(3)414-421, 1992.
Figlin, R.A., Piantadosi, S., Feld, R. Intracranial Recurrence of Carcinoma after Complete Surgical Resection of Stage I, II and III Non-Small Cell Lung Cancer. N Engl J of Med, 318(20):1300-1305, 1988.
This is a partial list. Full publications list available upon request. Information on this page may be self-reported and is subject to change at any time. Last updated: 07/08.